Yingjie Xu

TL;DR: It is shown that PTEN messenger RNA can be reintroduced into PTEN-null prostate cancer cells in vitro and in vivo via its encapsulation in polymer–lipid hybrid nanoparticles coated with a polyethylene glycol shell and this work provides proof-of-principle evidence of the restoration of mRNA-based tumour suppression in vivo.

TL;DR: The therapeutic role of Prohibitin1 (PHB1), a target protein that has not been systemically evaluated in vivo due to the lack of specific and effective inhibitors, is delineated and validated in treating non-small cell lung cancer (NSCLC) as evidenced by the drastic inhibition of tumor growth upon PHB1 silencing.

TL;DR: An exclusive overview of current state-of-the-art biomaterials and nanotechnology platforms for mRNA delivery, and discusses future prospects to bring these exciting technologies into clinical practice is provided.

TL;DR: The anticancer activity of novel benzimidazoles containing an oxetane or an amine group to enhance solubility is synthesized and characterized and significant cytotoxicity toward a variety of cancer cell types is demonstrated.

TL;DR: An NP platform with sustained siRNA-release properties, which can be self-assembled using biodegradable and biocompatible polymers and lipids, and which generates more effective tumor cell growth inhibition in vitro and in vivo than the lipofectamine complexes is presented.